Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study
- 1 April 2004
- journal article
- clinical trial
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 21 (5) , 645-653
- https://doi.org/10.1016/j.ejps.2004.01.005
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adultsBritish Journal of Clinical Pharmacology, 2003
- Pharmacokinetics, Safety, and Tolerability of Oral Posaconazole Administered in Single and Multiple Doses in Healthy AdultsAntimicrobial Agents and Chemotherapy, 2003
- Antifungal Activities of Posaconazole, Ravuconazole, and Voriconazole Compared to Those of Itraconazole and Amphotericin B against 239 Clinical Isolates of Aspergillus spp. and Other Filamentous Fungi: Report from SENTRY Antimicrobial Surveillance Program, 2000Antimicrobial Agents and Chemotherapy, 2002
- In Vitro Activities of Approved and Investigational Antifungal Agents against 44 Clinical Isolates of Basidiomycetous FungiAntimicrobial Agents and Chemotherapy, 2001
- Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N -acetyltransferase-2, and xanthine oxidase with the ″Cooperstown cocktail”Clinical Pharmacology & Therapeutics, 2000
- New agents for treatment of systemic fungal infectionsEmerging Drugs, 2000
- Novel triazole antifungal agentsExpert Opinion on Investigational Drugs, 2000
- Characterization of dextromethorphan N-demethylation by human liver microsomesBiochemical Pharmacology, 1994
- Pharmacokinetic Drug Interactions with Antimicrobial AgentsClinical Pharmacokinetics, 1993
- Validation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolizersClinical Pharmacology & Therapeutics, 1990